In November 2004, the FDA issued a final rule requiring HCT/P establishments to operate in accordance with Current Good Tissue Practice (CGTP) for the collection, donor screening, donor testing, processing, storage, labeling, packaging and distribution of HCT/Ps to prevent the introduction, transmission and spread of communicable diseases. The core CGTP requirements cover facilities, environmental controls, equipment, supplies and reagents, recovery, processing and processing controls, labeling controls, storage, and distribution (including receipt and predistribution shipment). The regulations for CGTPs are found in 21 CFR 1271 Subpart D; FDA recommendations for compliance with the regulations also are available.
StemCyte Introduces Insurance-Linked Cord Blood Access in Taiwan
November 12, 2025
AABB to Join CGT Supply Chain Discussions at Advanced Therapies USA
November 12, 2025
CMS Finalizes 2026 Medicare PFS Rule, Updates Biotherapies Payment Policies
November 05, 2025